<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710212</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00106363</org_study_id>
    <secondary_id>UM1AI104681</secondary_id>
    <nct_id>NCT04710212</nct_id>
  </id_info>
  <brief_title>Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies</brief_title>
  <acronym>SCENE</acronym>
  <official_title>Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies (SCENE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational cohort study to assess the frequency with which&#xD;
      neutropenic patients with hematologic malignancies and hematopoietic cell transplant (HCT)&#xD;
      recipients are colonized with fluoroquinolone-resistant Enterobacterales (FQRE) and the&#xD;
      clinical impact of FQRE colonization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, observational cohort study to assess the frequency with which&#xD;
      neutropenic patients with hematologic malignancies and hematopoietic cell transplant (HCT)&#xD;
      recipients are colonized with fluoroquinolone-resistant Enterobacterales (FQRE) and the&#xD;
      clinical impact of FQRE colonization.&#xD;
&#xD;
      The investigator will collect perianal swabs from patients receiving induction chemotherapy&#xD;
      for acute leukemia or undergoing hematopoietic stem cell transplantation (HCT), and who are&#xD;
      receiving fluoroquinolone (FQ) prophylaxis. FQRE colonization will be assessed by culture,&#xD;
      and the investigator will correlate FQRE colonization with the risk of Gram-negative&#xD;
      bacteremia during neutropenia.&#xD;
&#xD;
      Population: 410 adults with acute leukemia who are receiving induction chemotherapy and HCT&#xD;
      recipients who are receiving FQ prophylaxis during neutropenia.&#xD;
&#xD;
      Results of this study will be combined with a portion of subject data from an&#xD;
      identically-designed R01-funded study of FQRE colonization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gram-negative bloodstream infection (BSI)</measure>
    <time_frame>Until neutrophil recovery or 30 days after collection of the first swab in patients who do not have neutrophil recovery by 30 days</time_frame>
    <description>Gram-negative BSI during the episode of neutropenia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Colonization with FQRE and ESBL-E</measure>
    <time_frame>Within 4 days after initiation of chemotherapy</time_frame>
    <description>Colonization with fluoroquinolone-resistant Enterobacterales (FQRE) and Extended-spectrum-beta-lactamase-producing Enterobacterales (ESBL-E) upon initiation of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever</measure>
    <time_frame>Until neutrophil recovery or 30 days after collection of the first swab in patients who do not have neutrophil recovery by 30 days</time_frame>
    <description>Occurrence (Yes/No) of fever (≥38.0°C) during the episode of neutropenia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bloodstream infection (BSI)</measure>
    <time_frame>Until neutrophil recovery or 30 days after collection of the first swab in patients who do not have neutrophil recovery by 30 days</time_frame>
    <description>Any BSI during the episode of neutropenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit (ICU) admission</measure>
    <time_frame>Prior to neutrophil recovery or 30 days after collection of the first swab in patients who do not have neutrophil recovery by 30 days</time_frame>
    <description>Intensive care unit admission prior to recovery from neutropenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>Occurs within 90 days from the initiation of chemotherapy</time_frame>
    <description>90-day mortality from the initiation of chemotherapy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of and risk factors for acquiring FQRE and ESBL-E during the episode of neutropenia</measure>
    <time_frame>During the episode of neutropenia, up to 30 days</time_frame>
    <description>Acquisition of FQRE and ESBL-E in patients not initially colonized with these organisms</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">410</enrollment>
  <condition>Hematologic Malignancy</condition>
  <condition>Leukemia, Acute</condition>
  <condition>Neutropenia</condition>
  <condition>Bloodstream Infection</condition>
  <arm_group>
    <arm_group_label>Induction Chemotherapy for Acute Leukemia</arm_group_label>
    <description>Receiving induction chemotherapy for acute leukemia, and receiving fluoroquinolone (FQ) prophylaxis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hematopoietic stem cell transplantation (HCT)</arm_group_label>
    <description>Undergoing hematopoietic stem cell transplantation (HCT), and receiving fluoroquinolone (FQ) prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention.</intervention_name>
    <description>Observational study with no intervention.</description>
    <arm_group_label>Hematopoietic stem cell transplantation (HCT)</arm_group_label>
    <arm_group_label>Induction Chemotherapy for Acute Leukemia</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Perianal swabs are collected from subjects and only isolates are retained. Bloodstream&#xD;
      infection isolates are retained.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        410 adults with acute leukemia who are receiving induction chemotherapy and HCT recipients&#xD;
        who are receiving FQ prophylaxis during neutropenia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to provide informed consent&#xD;
&#xD;
          2. Male or female ≥18 years of age&#xD;
&#xD;
          3. Receiving intensive induction chemotherapy for acute leukemia or undergoing HCT&#xD;
&#xD;
          4. Receive fluoroquinolone prophylaxis during neutropenia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Expected to have &lt;7 days of neutropenia (absolute neutrophil count ≤500 cells/μL)&#xD;
             after receipt of chemotherapy (a) (acute leukemia cohort only)&#xD;
&#xD;
          2. First swab collected ≥5 days after onset of chemotherapy&#xD;
&#xD;
          3. First swab collected after the day of transplant (HCT cohort only)&#xD;
&#xD;
          4. Acute promyelocytic leukemia&#xD;
&#xD;
          5. Receiving chimeric antigen receptor (CAR)-T-cell therapy&#xD;
&#xD;
          6. Pregnant women as determined by clinician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Satlin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vance G Fowler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Satlin, MD, MS</last_name>
    <phone>212-746-7431</phone>
    <email>mjs9021@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nyssa Schwager</last_name>
    <phone>919-402-3528</phone>
    <email>nyssa.schwager@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Fransisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danaya Shariff</last_name>
      <phone>415-476-4862</phone>
    </contact>
    <investigator>
      <last_name>Sarah Doernberg, MD, MAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack Meridian Health</name>
      <address>
        <city>Nutley</city>
        <state>New Jersey</state>
        <zip>07110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariefel Vendivil</last_name>
      <phone>551-996-5828</phone>
    </contact>
    <investigator>
      <last_name>Scott Rowley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasha Vazquez</last_name>
      <phone>917-860-1449</phone>
    </contact>
    <investigator>
      <last_name>Samantha Jacobs, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>25714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Hendrickson</last_name>
      <phone>919-843-2541</phone>
    </contact>
    <investigator>
      <last_name>David van Duin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Siegel</last_name>
      <phone>503-494-1384</phone>
    </contact>
    <investigator>
      <last_name>Morgan Hakki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Liang</last_name>
      <phone>412-648-6536</phone>
    </contact>
    <investigator>
      <last_name>Ryan Shields, PharmD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FQRE</keyword>
  <keyword>Fluoroquinolone-resistant Enterobacterales</keyword>
  <keyword>Hematopoietic stem cell transplantation</keyword>
  <keyword>HCT</keyword>
  <keyword>Induction chemotherapy</keyword>
  <keyword>Hematologic Malignancy</keyword>
  <keyword>Acute Leukemia</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Bloodstream infection</keyword>
  <keyword>Perianal swab</keyword>
  <keyword>Gram-negative bacteremia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

